Parthenon: Bringing down immune exclusion in cancer

With backing from Pfizer and Taiho’s VC affiliates, Parthenon is developing a pipeline of cancer therapies designed to break down the physical barriers in the tumor microenvironment that shield tumors from immune cells. 

Parthenon Therapeutics Inc. announced Wednesday a $65 million series A round led by Northpond Ventures, Pfizer Ventures and Taiho Ventures, along with plans to address a largely uncharted area of tumor immunotherapy biology called immune exclusion...